ARWR logo

Arrowhead Pharmaceuticals, Inc.

ARWR
Healthcare|Biotechnology|US
$58.16
+0.70 (+1.22%)
Tangible Book / Share
$3.21
Cash / Share
$11.17

About

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Stock Price

+46.9%(1Y)
1M
-4.2%
3M
-33.6%
6M
-20.0%
YTD
-12.4%
1Y
+45.9%
3Y
+114.7%
5Y
-29.5%

Pipeline Summary

71 total trials
26
Phase 1
29
Phase 2
13
Phase 3
2
Phase 4
Completed: 37Recruiting: 11Terminated: 12Active: 4Available: 1Unknown: 2Withdrawn: 3Not Yet Recruiting: 1

Active Trials (15)

Statins In Intracerbral Hemorrhage
NCT03936361Intracerebral Hemorrhage
Phase 3Recruiting
Enrollment: 1,456 participants
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
NCT06700538Obesity
Phase 1Phase 2Active
Enrollment: 190 participants
Maternal Mindfulness: Depression and Postpartum Pain
NCT05400382Depression, Unipolar
N/ARecruiting
Enrollment: 75 participants
Azithromycin Before Induction
NCT06543290Infections
Phase 1Recruiting
Enrollment: 400 participants
A First-In-Human Study of ARO-033 in Adult Participants
NCT07662096Age-related Macular Degeneration
Phase 1Recruiting
Enrollment: 84 participants

BioScore

6/10
Watchlist

Key Facts

Market Cap$8.22B
Employees711 (+17% YoY)
CEOChristopher R. Anzalone
IPO DateDec 16, 1993
Beta1.37
52-Week Range$37.06 – $95.49
Avg Volume1,847,238
ExchangeNASDAQ

Ownership

Float86.7%
Shares Outstanding141.3M

Recent Insider Trades

OLUKOTUN ADEOYE YSELL
Aug 18, 20262,000 shares @ $86.96
PERRY MICHAEL SSELL
Aug 18, 202611,600 shares @ $87.30
Cohen Matthew GregoryAWARD
Jun 15, 202611,882 shares
Cohen Matthew GregoryOTHER
Jun 15, 20260 shares
Lu HongboSELL
May 12, 20262,970 shares @ $76.88

Peers

ALNYAlnylam Pharmaceuticals, Inc.
$20.89B
ARCTArcturus Therapeutics Holdings Inc.
$294.2M
IONSIonis Pharmaceuticals, Inc.
$6.55B
PRQRProQR Therapeutics N.V.
$190.5M
SLNSilence Therapeutics plc
$931.9M
WVEWave Life Sciences Ltd.
$663.7M
Data last updated: Nov 9, 2026, 03:56 AM